Tetracyclic Organism: Join hands with Cambridge Technology in Australia to develop drugs for liver cancer.
Join hands with Cambridge Technology Australia.
165438+1On October 28th, Beijing Sihuan Biopharmaceutical Co., Ltd., a holding subsidiary of Sihuan Bio (0005 18), signed a technical cooperation agreement with Cambridge Life Science and Technology Co., Ltd. in Melbourne, Australia to * * * develop an interleukin -2 sublingual buccal tablet for treating liver cancer.
According to the agreement between the two parties, Cambridge Science and Technology plans to carry out Phase II and Phase III clinical trials of CSDS * IL-2 in China, and plans to register CSDS * IL-2 as an interleukin -2 sublingual buccal tablet for the treatment of liver cancer in China. Beijing Sihuan cooperated with Cambridge Science and Technology to carry out the next clinical trial, and Cambridge Science and Technology provided the technology and funds for the clinical trial; Beijing Sihuan helped Cambridge Science and Technology to register in China, and provided a special micro-packaging workshop for Cambridge Science and Technology to produce raw materials and preparations for clinical trials, so as to jointly explore domestic and foreign markets.
According to the data, Beijing Sihuan is a high-tech enterprise integrating science, industry and trade, and is committed to the research, development, production and sales of bioengineering products. Its main products include recombinant human interleukin-2 for injection, recombinant human erythropoietin and recombinant human granulocyte stimulating factor. Beijing Sihuan has its own scientific research laboratory and distribution channels for production and products.
Cambridge Technology is an Australian company dedicated to life science, which mainly studies the development of anticancer therapy by using the technology of cytokine sublingual drug delivery system (CSDS). Cambridge Science and Technology successfully completed the preclinical trial of CSDS * IL-2 in China. This drug uses the technology of cytokine sublingual delivery system to treat liver cancer and other cancers that can be treated with IL-2, and has applied for an international patent. At present, it is planned to carry out phase II and III clinical trials of CSDS * IL-2 in China, and it is planned to register CSDS * IL-2 as IL-2 sublingual buccal tablets for the treatment of liver cancer in China.
According to Tetracyclic Biology, the technology of cytokine sublingual delivery system (CDSD) is the latest cytokine delivery technology in the world at present, and the successful development of CSDS*IL2-2 as an interleukin -2 sublingual buccal tablet for the treatment of liver cancer will replace the current injection. On the one hand, because the IL -2 sublingual buccal tablet directly enters the lymphatic system to regulate the immunity of the body, unlike the injection which indirectly enters the lymphatic system through blood, the IL -2 sublingual buccal tablet can greatly improve the bioavailability of IL -2, better regulate the immune function, increase the anti-cancer effect, avoid clinical adverse reactions such as fever caused by IL -2 injection and the pain caused by injection, and improve the safety and effectiveness of medication. On the other hand, Interleukin -2 sublingual buccal tablets are exclusively produced by patent protection and have good market value.
It is reported that, with the mutual consent, Cambridge Science and Technology will set up a joint venture with Beijing Sihuan to promote the production and distribution of CSDS*IL2 in China and Asia. The two sides will discuss an exclusive agency agreement, agreeing that CS-DS * IL2 will use the technology of Cambridge Science and Technology, and it will be authorized to set up a factory in China.
Beijing Sihuan will assist the joint venture company and license Cambridge Science and Technology to register its product CSDS * IL2； with the product master document of Beijing Sihuan Interleukin II; And provide enough interleukin -2 for the clinical trial of its product CSDS IL2 in China. In addition, Beijing Sihuan will build or entrust a special micro-packaging workshop for the joint venture company, so that the product output can meet the needs of China and other Asian countries, such as Japan, Thailand, Taiwan Province, India and Indonesia. On the basis of mutual benefit, Beijing Sihuan will further discuss the supply agreement of interleukin -2 with the joint venture company.
Cambridge Science and Technology said that it hopes to discuss other possible cooperation projects with Beijing Sihuan, such as research and development, production and distribution of some biological proteins. After mutual approval, the technology of cytokine sublingual delivery system can be applied to products such as tetracyclic interferon, recombinant human erythropoietin and recombinant human granulocyte stimulating factor. Cambridge Science and Technology hopes to explore other possible business opportunities with Beijing Sihuan to facilitate the development, production and distribution of the joint venture company in China and Asia, as well as the approval and use of CSDS technology in other cancer treatment drugs and bioengineering products. (Securities Times)
Personally, don't chase after heights! ! !